 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 1 of 6  
 
INFORMED CONSENT DOCUMENT  – Aim 2 Participants  
 
Project Title:  Development and validation of a shared -decision making tool for initiation of 
treatment in patients with Hepatitis C infection and chronic kidney disease  
 Project HELP  (Helping Empower L iver and kidney Patients)  
 
Principal Investigator:  Mary C. Politi, PhD  
 Research Team Contact:  Nerissa George, MPH (314) 747- 5657  
 
This consent form describes the research study and helps you decide if you want to participate.  It provides important information about what you will be asked to do during the study, about the risks and benefits of the study, and about your rights as a re search participant.  
• You should read and understand the information in this document including the procedures , risks, and potential benefits  
• If you have any questions about anything in this form, you should ask the research team for more information  before you agree to participate .   
• You may also wish to talk to your family or friends about your participation in this study.  
• Do not agree to participate in this study unless the research team has answered your questions and you decide that you want to be part of this study.  
 
WHAT IS THE PURPOSE OF THIS STUDY?   
This is a research study. We invite you to participate in this research study  because y ou have 
Hepatitis C and Kidney Disease. The purpose of this research study is to test a web -based tool 
we developed for people with Hepatitis C and Kidney Disease. We want to learn whether this tool could help people learn about Hepatitis C and Kidney disease and choose a treatment plan that works best for them . This tool does not  replace a conversation with a clinician  and is to be 
used to prepare for visits with a clinician .  
 
WHAT WILL  HAPPEN DURING THIS STUDY?  
If you agree to participate, we will ask you to fill out a brief survey. Next, we will ask you to look at some information a bout kidney disease and Hepatitis C . Then we will ask you fill out 
another survey. Everything you do for the study can  be completed on a computer provided by us , 
on your own computer, or you can view a paper version. Y ou may skip any question that you do 
not wish to answer .  
 
HOW MANY PEOPLE WILL PARTICIPATE?  
About 70 people will take part in this part of the study.   
 
HOW LONG WILL I BE IN THIS STUDY?  
If you agree to take part in this study, your i nvolvement will last for about 30- 45 minutes.  
 
 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 2 of 6  
 
WHAT ARE THE RISKS OF THIS STUDY?  
One risk of participating in this study is that confidential information about you may be accidentally disclosed. We will use our best efforts to keep the information about you secure, and 
we think the risk of accidental disclosure is very small.  Please see the section in this consent form titled “How will you keep my information confidential?”  for more information.  
 
WHAT ARE THE BENEFITS OF THIS STUDY?  
You will not benefit from being in this study. However, we hope that, in the future, other people might benefit from this study because y our answers may help us learn the best ways to support 
individuals’ decisions about treating h epatitis c  and kidney disease . 
 
WILL IT COST ME ANYTHING TO BE IN THIS S TUDY?  
You will not have any costs for being in this research study.   
 
WILL I BE PAID FOR PARTICIPATING?  
You will be paid for being in this research study. You will receive a $20 gift card to thank you 
for your time. We will ask for your social security number (SSN) in order for us to pay you. You may choose to participate even if you do not wish to provide your social security number (SSN) for this purpose. If your social security number is obtained for payment purposes only, it will not be retained for research purposes.  
 
WHO IS FUNDING THIS STUDY?  
Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co., Inc , is funding this research 
study. This means that Washington University is receiving payments from Merck Sharp & Dohme Corporation to support the activities that are required to conduct the study. No one on the research team will receive a direct payment or increase in salary from Merck Sharp & Dohme Corporation for conducting this study.    
 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?  
We will keep your participation in this study confidential to the extent permitted by law. However, it is possible that other people such as those indicated below may become aware of your participation in this study and may inspect and copy records pertaining to this research. Some of these records could contain information that personally identifies you.  
• Government representatives, (including the Office for Human Research Protections) to 
complete federal or state responsibilities  
• Merck Sharp & Dohme C orporation, a subsidiary of Merck & Co., Inc . 
• University representatives, to complete University responsibilities  
• Washington University’s Institutional Review Board (a committee that oversees the 
conduct of resear ch involving human participants ) and Human Research Protection 
Office. The Institutional Review Board has reviewed and approved this study.  
 To help protect your confidentiality, we will give your study data  a unique number that will be 
used on all parts of the survey. Your name, phone number, or other identifiers will not be listed on the survey. Any information you enter on the computer survey will be protected with a 
 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 3 of 6  
 
password so that only the study team can access it. We will keep any paper copies in a locked filing cabinet in a locked offic e suite. If we write a report or article about this study or share the 
study data set with others, we will do so in such a way that you cannot be directly identified.  
 The research team will send study results to  Merck Sharp & Dohme Corporation, a subsidia ry of 
Merck & Co., Inc  (Merck). Information sent to Merck  will not be identifiable. Only information 
that does not have your name or identifying information will be sent so that they can also learn how to talk about treatment options for hepatitis C and chronic kidney disease. In the future, 
Merck  may continue to use your health information that is collected as part of this study. You 
will not be identified by name in any reports or presentations about this study.    
 
Are there additional protections for my health information? 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this research, you must give the research team permission to use and disclose (share) your PHI for the study as explained in this consent for m.  The  research team will follow state and federal 
laws and may share your health information  with  the agencies and people listed under the 
previous section titled, “ How will you keep my information confidential ” 
 Once your health information is shared wi th someone outside of the research team, it may no 
longer be protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form  or as 
permitted or required by law .  When possible, the research team will make sure  information 
cannot be linked to you (de -identified).  Once information is de -identified, it may be used and 
shared for other purposes not discussed in this consent form. If you have questions or concerns 
about your privacy and the use of your PHI, please contact the University’ s Privacy Officer at 
866-747-4975.  
 Although you will  not be allowed to see  the study information, you may be given access to your 
health care records by contacting your health care provider.  
 If you decide not to sign this form, it will not affect  
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled.  
 However, it will not be possible  for you to take part in the study.  
 
If you sign this form:  
• You authorize the use of your PHI for this research 
• This authorization does not expire. 
• You may later change your mind and not let the research team use or share your 
information (you may r evoke your authorization).  
 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 4 of 6  
 
 
• To revoke your authorization, complete the withdrawal letter, found in the Participant 
section of the Human Research Protection Office website at http://hrpo.wustl.edu/participants//withdrawing -from -a-study/
 or you may request that 
the investigator send you a copy of the letter.  
• If you revoke your authorization:  
o The research team may only use and share information already collected for the study.  
o Your information may still be used and shared as  necessary to maintain the 
integrity o f the research, for example, to account for a participant’s 
withdrawal from the research study  or for safety reasons.  
o You will not be allowed to continue to participate in the study.  
 
Can we contact you by email? 
We would like to contact you by email for  the purposes listed below.  Some of these emails may 
contain  health information  that identifies you .. 
• Links to the surveys  
• Information about an appointment time, if we make one  
• Reminder emails about completing your surveys, if you are completing them at 
home    
 Only the research team will  have access to your email communications. We will only 
communicate by email  to send you the information listed above. If you have any questions  or 
need to contact us for an urgent or emergent situation, please contact the research team member identified at the top of this document.   
 
You should be aware that there are risks associated with sending  your health information via 
email .   
• There is always a risk that the message could be intercepted or  sent to the wrong 
email address. To avoid sending messages to the wrong email address, the first email 
we send you will be a test message to ensure we have the correct email address.  
• When us ing any computer you should be careful to protect your username and 
password. Make sure you log -out before getting up from the computer.   
• If you share a home computer with other family members, and do not want them to 
know you are participating in this study make sure you  provide  an email add ress that 
only you can access.  
• Your employer will have access to any email communications sent or received on any electronic devices used for work or through a work server . 
  Do you agree to allow us to send your  health information via email?   
 
_____ Yes  _____ No 
Initials   Initials  
 
 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 5 of 6  
 
IS BEING IN THIS STUDY VOLUNTARY?  
Taking part in this research study is completely voluntary. You may c hoose not to take part at 
all. If you decide to be in this study, you may stop participating at any time. Any data that was 
collected as part of your participation in the study will remain as part of the study records and cannot be removed. You will be told in a timely manner about significant new information that might affect your  decision to stay in the study.  
 If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or lose any benefits for which you otherwise qualify.   
 
WHAT IF I DECIDE TO WITHDRAW FROM  THE STUDY?  
You may withdraw  by telling the study team you are no longer interested  in participating in the 
study .  
 
WHAT IF I HAVE QUESTIONS?  
We encourage you to ask questions.  If you have any questions about the research study itself or if you feel you have been harmed in any way, please contact:  Mary C. Politi, PhD at (314) 747-
1967.     If you have questions, concerns, or complaints about your rights as a research participant please contact the Human Research Protection Office at  660 South Euclid Avenue, Campus Box 8089, 
St. Loui s, MO  63110, 1- (800) -438-0445, or email hrpo@wustl.edu
. General information about 
being a research participant can be found on the Human Research Protection Office web site, 
http://hrpo.wustl.edu . To offer input about your experiences as a research participant  or to speak 
to someone other than the research staff, call the Human Research Protection Office at the 
number above.  
 
  
   
 
   
 
 FOR IRB USE ONLY  
IRB ID #: 201707154 
APPROVAL DATE: 08/29/17  
RELEASED DATE: 10/02/17  
EXPIRATION DATE: 08/01/18  
 
 
Page 6 of 6  
 
This consent form  is not a contract. It is a written explanation of what will happen during the 
study if you decide to participate. You are not waiving any legal rights by agreeing to participate 
in this study.   
 Your signature indicates that this research study has been explained to you, that your questions have been answered, and that you agree to take part in this study.  You will receive a signed copy 
of this form.  
 
 
Do not sign this form if today’s date is after EXPIRATION DATE: 08/01/18 . 
 
 
_________________________________________________________________________ 
(Signature of Participant)      (Date)  
 
 
___________________________________________ 
(Participant's name – printed)  
 
 
Statement of Person Who Obtained Consent  
 The information in this document has been discussed with the participant  or, where appropriate, 
with the participant ’s legally authorized representative.  The participant has indicated that he or 
she understands the risks, benefits, and procedures involved with participation in this research 
study.  
  _________________________________________________________________________ (Signature of Person who Obtained Consent)    (Date)  
  ____________________________________________ (Name of Person who Obtained Consent -  printed)  